XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...

Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of ...

Solid Biosciences (SLDB) stock was launched by Truist with a Buy rating based on positive catalysts and attractive valuation.

The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...

Scientists at La Jolla Institute for Immunology (LJI) have discovered how a mutated gene kicks off a dangerous chain of ...

Continuing significant advancements in the field of xenotransplantation, surgeon-scientists from the University of Maryland ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

Using a new artificial intelligence method, researchers at Columbia University Vagelos College of Physicians and Surgeons can accurately predict the activity of genes within any human cell, ...